It would test Merck Acquisitions Emboldened regulators

For those who attended the two-day regulatory workshop on strengthening antitrust enforcement in the pharmaceutical industry, the message could not have been clearer: the days when megafusions could have passed without much scrutiny are over.

It was almost as if he were presenting a trial case, The Wall Street Journal based in New Jersey two days later. Merck & Co. was looking to buy Seattle area-biotech Seagen which is now worth just over $ 30 billion. The report stated that there could be other suitors and that reaching an agreement “could be difficult because of the greater risk of a regulatory challenge”.